Buy (150 RUB)
Generate QR code
Open Access
Subscription or Fee Access
Anogenital psoriasis. Experience of netakimab therapy
https://doi.org/10.33667/2078-5631-2025-8-83-88
Abstract
Introduction. Diagnosis of anogenital psoriasis is complicated by the lack of awareness of doctors and the shyness of patients. The total lesion area and the severity of anogenital psoriasis are often in inverse proportion, which requires the use of systemic therapy. Aim. To present our experience of netakimab monotherapy in anogenital psoriasis.
Materials and methods. 31 adult patients (n=31) with anogenital psoriasis were under observation. The severity of the psoriatic lesion was determined using index sPGA-G (static Physician’s Global Assessment of Genitalia). The assessment was carried out before the start of treatment and then every 4 weeks up to 52 weeks. All patients on an outpatient basis received interleukin‑17 inhibitor (IL‑17) monotherapy with netakimab at a dose of 120 mg in the form of two subcutaneous injections of 1 ml (60 mg) of the drug, each administered once a week at weeks 0, 1 and 2, then 1 time every 4 weeks. The total duration of treatment for each patient was 52 weeks. Dermatological Quality of Life Index (DLQI) were determined by questionnaires before the start of treatment, at the 12th and 52nd weeks. The safety of netakimab was evaluated based on the development of adverse events and local reactions to the administration of the drug.
Results. The results of the study for 52 weeks showed high efficacy of netakimab. 48.4% of patients achieved complete clinical recovery (sPGA0) after 12 weeks of treatment, 67.7% after 24 weeks, and 77.4% after 52 weeks, the quality of their life improved by 6,6 times. There weren’t any cases of early withdrawal due to adverse events and cases of serious adverse events.
Conclusion. Based on the study results we recommend netakimab for treatment of patients with anogenital psoriasis.
About the Authors
M. I. Kurdina
JSC MEDSI 2
Russian Federation
Russian Federation
Kurdina Maria I., DM Sci (habil.), professor, dermatovenerologist
3A, Gruzinskiy Lane, Moscow
N. G. Kolenko
JSC MEDSI 2; Peoples’ Friendship University of Russia named after Patrice Lumumba (RUDN University)
Russian Federation
Russian Federation
Kolenko Natalia G., PhD Med, cosmetologist, dermatovenerologist; associate professor at Dept of Nursing Management of the Medical Institute
16, Krasnaya Presnya St., Moscow
References
1. Dopytalska K., Sobolewski P., Błaszczak A., Szymańska E., Walecka I. Psoriasis in special localizations. Reumatologia. 2018; 56 (6): 392–398.
2. Ryan C., Menter A., Guenther L. et al. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. British Journal of Dermatology. 2018; 179 (4): 844–852.
3. Meeuwis K.A., de Hullu J.A., IntHout J. et al. Genital psoriasis awareness program: physical and psychological care for patients with genital psoriasis. // Acta Dermato-Venereologica. 2015; 95: 211–216.
4. Wang G., Li C., Gao T., Liu Y. Clinical analysis of 48 cases of inverse psoriasis: a hospital-based study. European Journal of Dermatology. 2005; 15 (3): 176–178.
5. Meeuwis KAP, Potts Bleakman A., van de Kerkhof PCM, Dutronc Y., Henneges C., Kornberg L.J., Menter A. Prevalence of genital psoriasis in patients with psoriasis. Journal of Dermatological Treatment. 2018; 29 (8): 754–760.
6. van de Kerkhof PCM. Clinical Features. / In: van de Kerkhof 4. PCM, editor. Textbook of Psoriasis. Oxford: Blackwell Publishing Ltd. 2003: 3–29.
7. Stoof T.J., van der Meijden wI. Psoriasis. / In: van der Meij 5. den WI, ter Harmsel WA, editors. Vulvapathologie. Assen: Koninklijke Van Gorcum BV. 2007: 137–146.
8. da Silva N., Augustin M., Hilbring C., Braren-von Stülpnagel C.C., Sommer R. Psychological (co)morbidity in patients with psoriasis: the impact of pruritus and anogenital involvement on symptoms of depression and anxiety and on body dysmorphic concerns – a cross-sectional study. BMJ Open. 2022; 12 (9): e 055477.
9. Molina-Leyva A., Almodovar-Real A., Ruiz-Carrascosa J.C., Naranjo-Sintes R., Serrano-Ortega S., Jimenez-Moleon J.J. Distribution pattern of psoriasis affects sexual function in moderate to severe psoriasis: A prospective case series study. Journal of Sexual Medicine. 2014; 11: 2882–2889.
10. Cather J.C., Ryan C., Meeuwis K., Potts Bleakman A.J., Naegeli A.N., Edson-Heredia E., Poon J.L., Jones C., Wallace A.N., Guenther L., Fretzin S. Patients’ Perspectives on the Impact of Genital Psoriasis: A Qualitative Study. Dermatology and Therapy (Heidelb). 2017; 7 (4): 447–461.
11. Ryan C., Sadlier M., De Vol E., Patel M., Lloyd A.A., Day A., Lally A., Kirby B., Menter A. Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. // Journal of the American Academy of Dermatology. 2015; 72 (6): 978–983.
12. Shah SFH., Merchant S.A., Shah, S.A. Female sexual dysfunction in psoriasis: a systematic review and meta-analysis using the Female Sexual Function Index. International Journal of Impotence Research. 2024; 36 (3): 232–241.
13. Salim A., Wojnarowska F. Skin diseases affecting the vulva. Current Obstetrics and Gynaecology. 2005; 15 (2): 97–107.
14. Meeuwis K.A., de Hullu J.A., Massuger L.F., van de Kerkhof P.C., van Rossum M.M. Genital psoriasis: a systematic literature review on this hidden skin disease. Acta Dermato-Venereologica. 2011; 91: 5–11.
15. Kapila S., Bradford J., Fischer G. Vulvar psoriasis in adults and children: a clinical audit of 194 cases and review of the literature. Journal of Lower Genital Tract Disease. 2012; 16 (4): 364–371.
16. Puzenat E., Bronsard V., Prey S., Gourraud P.A., Aractingi S., Bagot M., Cribier B., Joly P., Jullien D., Le Maitre M., Paul C., Richard-Lallemand M.A., Ortonne J.P., Aubin F. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. Journal of the European Academy of Dermatology and Venereology. 2010; 24 (2):10–16.
17. Merola J.F., Bleakman A.P., Gottlieb A.B., Menter A., Naegeli A.N., Bissonnette R., Guenther L., Sullivan J., Meeuwis K., See K., Duffin K.C. The Static Physician’s Global Assessment of Genitalia: A Clinical Outcome Measure for the Severity of Genital Psoriasis. Journal of Drugs in Dermatology. 2017; 16 (8): 793–799.
18. Gottlieb A.B., Kirby B., Ryan C. et al. The Development of a patient-reported outcome measure for assessment of genital psoriasis symptoms: The Genital Psoriasis Symptoms Scale (GPSS). Dermatology and Therapy (Heidelb). 2018; 8: 45–56.
19. Kimball A.B., Naegeli A.N., Edson-Heredia E., Lin C-Y., Gaich C.,, Nikaï E.,, Wyrwich K.,, Yosipovitch G. Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016; 175 (1): 157–62. doi: 10.1111/bjd.14464.
20. Ferrara F., Verduci C., Laconi E., Mangione A., Dondi C., Del Vecchio M., Carlevatti V., Zovi A., Capuozzo M., Langella R. Current therapeutic overview and future perspectives regarding the treatment of psoriasis. International Immunopharmacology. 2024; 143 (1): 113388.
21. Menter A., Gelfand J.M., Connor C., Armstrong A.W., Cordoro K.M., Davis DMR, Elewski B.E., Gordon K.B., Gottlieb A.B., Kaplan D.H. et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. Journal of the American Academy of Dermatology. 2020; 82: 1445–1486.
22. Kelly A., Ryan C. Genital Psoriasis: Impact on Quality of Life and Treatment Options. American Journal of Clinical Dermatology. 2019; 20 (5): 639–646.
23. Strober B., Ryan C., van de Kerkhof P., van der Walt J., Kimball A.B., Barker J., Blauvelt A. International Psoriasis Council Board Members and Councilors. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. Journal of the American Academy of Dermatology. 2020; 82 (1): 117–122.
24. Hong J.J., Mosca M.L., Hadeler E.K., Brownstone N.D., Bhutani T., Liao W.J. Genital and Inverse/Intertriginous Psoriasis: An Updated Review of Therapies and Recommendations for Practical Management. Dermatology and Therapy (Heidelb). 2021; 11 (3): 833–844.
25. Armstrong A.W., Puig L., Joshi A., Skup M., Williams D., Li J., Betts K.A., Augustin M. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis. JAMA Dermatology. 2020; 156: 258–269.
26. Kubanov A.A., Karamova A.E., Pritulo O.A., Arshinsky M.I., Znamenskaya L.F., Chikin V.V. et al. Psoriasis: clinical guidelines. M.; 2023. 78 p. Access mode: https://www.rodv.ru/upload/iblock/a84/q6gxj2hn1mip4m1vaaqg1vyvsy05u11y.pdf
27. Sokolovsky E.V., Kokhan M.M. Evidence-based aspects of genital psoriasis therapy using genetically engineered biological therapy. Bulletin of Dermatology and Venereology. 2021; 97 (2): 50–55. (In Russ.).
28. Gerdes S., Asadullah K., Hoffmann M., Korge B., Mortazawi D., Wegner S., PersonkeY., Gomez M., Sticherling M.. Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab. Journal of the European Academy of Dermatology and Venereology. 2022; 36 (9): 1568–77.
Review
For citations:
Kurdina M.I., Kolenko N.G. Anogenital psoriasis. Experience of netakimab therapy. Medical alphabet. 2025;(8):83-88. (In Russ.) https://doi.org/10.33667/2078-5631-2025-8-83-88
Views:
43
Email this article 